Nectar Lifesciences Ltd
NECLIFE
Company Profile
Business description
Nectar Lifesciences Ltd is an India-based pharmaceutical company. It is engaged in manufacturing specialized pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and finished dosage formulations. It operates in the business segment of Pharmaceuticals Products, The company's product includes cefixime trihydrate, cefdinir, cefprozil, cefoxitin sodium, cefpirome sulphate, and others. Geographically, it derives a majority of its revenue from India.
Contact
SCO 38-39, Sector 9-D
B-1011/1012, 10th Floor NAURANG HOUSE
Chandigarh160009
INDT: +91 1725047915
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2025
Employees
1,686
Stocks News & Analysis
stocks
Australian stocks will crush housing over the next decade, one year on
James Gruber looks back on his forecast for Australian equities and the housing market
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
stocks
What next for Tesla as 2024 deliveries disappoint?
Tesla shares started the year on a sour note. We think they continue to price in ambitious growth going forward.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,599.40 | 56.50 | 0.66% |
| CAC 40 | 7,490.07 | 0.72 | 0.01% |
| DAX 40 | 20,462.78 | 122.21 | 0.60% |
| Dow JONES (US) | 42,528.36 | 178.20 | -0.42% |
| FTSE 100 | 8,263.29 | 18.01 | 0.22% |
| HKSE | 19,279.84 | 167.74 | -0.86% |
| NASDAQ | 19,489.68 | 375.30 | -1.89% |
| Nikkei 225 | 39,981.06 | 102.24 | -0.26% |
| NZX 50 Index | 13,043.11 | 1.05 | 0.01% |
| S&P 500 | 5,909.03 | 66.35 | -1.11% |
| S&P/ASX 200 | 8,349.10 | 64.00 | 0.77% |
| SSE Composite Index | 3,230.17 | 0.52 | 0.02% |